27 results about "Proto-Oncogenes" patented technology

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful for treating subjects having a disorder or disease that can be treated by reducing the level of VAV1, such as cancer, inflammatory or autoimmune disorders.

The invention discloses a method, a system and equipment for detecting internal tandem repeat and a storage medium, and the key points of the technical scheme are as follows: obtaining a first reference sequence according to at least one target exon sequence corresponding to a protooncogene, and obtaining a second reference sequence according to at least one target intron sequence corresponding to the protooncogene; comparing the sequencing data of the to-be-detected sample to the second reference sequence to obtain a first comparison result, extracting an uncompared sequence from the sequencing data according to the first comparison result, and comparing the uncompared sequence to the first reference sequence to obtain a second comparison result; and determining a first detection result according to the second comparison result and a first reference sequence, and performing false positive filtering on the first detection result to obtain a second detection result. According to the invention, false positive can be reduced so as to ensure the accuracy and reliability of subsequent analysis.

The disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade the protooncogene VAV 1 protein (VAV1). These chemical entities are useful, for example, in the treatment of subjects suffering from inflammatory or autoimmune disorders (e.g., human subjects).

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful for treating subjects having a disorder or disease that can be treated by reducing the level of VAV1, such as cancer, inflammatory or autoimmune disorders.

The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade the proto-oncogene VAV1 protein (VAV1). The chemical entities are useful, for example, for treating subjects (e.g., human subjects) with inflammatory or autoimmune disorders.

Methods and compositions for gene therapy of retinal degeneration related to mutations in MER proto-oncogene, tyrosine kinase (MERTK).

The application relates to a circular triplex-forming oligonucleotide, a preparation method and application in preparation of tumor-targeting drugs. The circular triplex-forming oligonucleotide (Cir-TFO) is composed of two oligonucleotide chains A and B, each of which comprises a first complementary sequence, a first connecting sequence, a target sequence, a second connecting sequence and a second complementary sequence from the 5' end to the 3' end. The first complementary sequences of the two oligonucleotide chains A and B are reversely and complementarily connected, and the second complementary sequences are reversely and complementarily connected to form a closed ring structure. The target sequence is a TFO sequence capable of forming a triplex structure with double-stranded DNA in the promoter region of a target gene through Hoogsteen hydrogen bonds, and the target gene is selected from a proto-oncogene, an anti-apoptotic gene or a tumor metabolism-related gene.

The present disclosure relates to proteolysis-inducing compounds against the proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild-type RET or a mutant form of RET, which are useful in the treatment of diseases and disorders mediated by said protein, and have formula (I): TIFF2025540907000060.tif43113

Provided herein are compounds of formula (I) and salts and compositions thereof which find utility as modulators of Cbl-b in the treatment of various forms of cancer.

TIFF2025540906000076.tif4057 The present disclosure relates to protein-binding compounds of the proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild-type RET or a mutant form of RET, that are useful for the treatment of diseases and disorders mediated by said protein and have formula (I):

The present application relates to the field of cancer cell identification, and particularly relates to a method and system for identifying different types of cancer cells of a renal pelvis cancer patient based on urine, the method comprising: collecting a urine sample, obtaining a detection sample by using the urine sample; sequencing the detection sample to obtain a cell expression profile of the detection sample; obtaining cell expression profile data of a mixed urothelial cell subpopulation by using the cell expression profile, the mixed urothelial cell subpopulation comprising normal urothelial cells and cancerous urothelial cells; extracting different proto-oncogene expression data from the cell expression profile data of the mixed urothelial cell subpopulation; analyzing the different proto-oncogene expression data to obtain a cancer cell ratio and identify different types of cancer cells. The present method quickly and accurately obtains different types of cancerous urothelial cells through non-invasive examination and proto-oncogene expression profile data, and provides a reference and basis for preoperative neoadjuvant therapy of renal pelvis cancer.

The present disclosure provides compounds of formula (I): which induce proteolysis of the proto-oncogene tyrosine protein kinase receptor (RET), which may be either wild-type or mutant RET (useful in the treatment of diseases and disorders mediated by said protein): This relates to the compound represented by TIFF2026506696000135.tif42150.

The present disclosure relates to CRISPR-related systems and components for targeting, editing and / or modulating the expression of FLI-1 (Freund Virus Leukemia Integration 1 Transcription Factor; Fli-1 prooncogene, ETS Transcription Factor) genes. The disclosure also relates to methods and uses thereof related to engineered cells comprising T cells or T cell precursors.

The invention provides a lentiviral vector for constructing a cell model for detecting carcinogenicity of chemical substances, a recombinant cell as well as a preparation method and application of the lentiviral vector. The lentiviral vector comprises a human c-myc gene promoter, an operably connected reporter gene and a selection marker gene. Recombinant cells capable of stably expressing reporter genes can be obtained by transfecting host cells with the vector, the activation effect of chemical substances on c-myc channels can be sensitively reflected through signal changes of the reporter genes, and rapid and visual preliminary screening of carcinogenicity is achieved. Furthermore, the recombinant cell is combined with a CRISPR-Cas9 sgRNA library targeting DNA damage repair, epigenetic regulation, tumor inhibition and proto-oncogene to construct an integrated screening system, so that the carcinogenic potential of chemical substances can be evaluated, key genes and molecular mechanisms of genetic toxicity of the chemical substances can be systematically revealed, and the application prospect is broad. And an efficient tool is provided for toxicology risk assessment and mechanism research.

This disclosure relates to CRISPR-related systems and components for targeting, editing, and / or regulating the expression of the FLI-1 (Friend virus leukemia integration 1 transcription factor, Fli-1 proto-oncogene, ETS transcription factor) gene. This disclosure also relates to methods and applications relating to genetically modified cells, including T cells or T cell progenitor cells.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

The present invention relates to bispecific antibodies comprising a first variable domain that can bind to an extracellular portion of the epidermal growth factor receptor (EGFR) and a second variable domain that can bind to an extracellular portion of the MET proto-oncogene, tyrosine kinase receptor (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some embodiments, the bispecific antibody is an IgG1-format antibody having a 1:1 anti-cMET, anti-EGFR stoichiometry. In some embodiments, the antibody has a variable domain that can bind to EGFR and a variable domain that can bind to cMET.

The present disclosure relates to protein degradation inducing compounds for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorders mediated by said protein and having the Formula (I).

The invention discloses application of a pegylated interferon and proto-oncogene product targeted inhibitor in synergistic treatment of kidney cancer. Specifically, the invention provides an application of an active ingredient combination, the active ingredient combination comprises a PEG interferon and a proto-oncogene product targeting inhibitor, and the combination is used for preparing a medicine composition for co-treating kidney cancer. The active component composition can effectively and synergistically inhibit kidney cancer, and can remarkably reduce toxic and side effects, so that the composition can be widely applied to targeted treatment of tumors.

Methods and compositions for gene therapy of retinal degeneration associated with mutations in the MER protooncogene tyrosine kinase (MERTK).

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some aspects, the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some aspects, the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

Disclosed herein are methods for predicting responsiveness to an immune checkpoint inhibitor, such as a Casitas B-lineage lymphoma proto-oncogene b inhibitor (CBL-Bi), using a biomarker signature. Additionally disclosed herein are methods for determining a biomarker signature indicative of responsiveness to an immune checkpoint inhibitor, such as a Casitas B-lineage lymphoma proto-oncogene b inhibitor (CBL-Bi). Additionally disclosed herein are methods for determining effects of a Casitas B-lineage lymphoma proto-oncogene b inhibitor (CBL-Bi) administered to a subject.

Provided herein are compositions and methods for preventing ocular vascular regression, preserving visual function, or both, comprising: identifying a subject in need of treatment for ocular vascular regression; and providing the subject with an effective amount of an agent that is: an agonist that increases expression of at least one gene selected from: ETS-Related Gene (ERG), Fli-1 Proto-Oncogene; ETS Transcription Factor (FLU); KEF transcription factor 2 (KLF2); KEF transcription factor 4 (KLF4); or a Piezo-Type Mechanosensitive Ion Channel Component 1 (PIEZO1) agonist, or both; wherein the agent is provided in an amount sufficient to prevent the ocular vascular regression, preserving visual function, or both.

Compounds of Formula (I) which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET, are described. The compounds can be used to treat a disorder mediated by RET protein, for example a cancer or a tumor.

The present invention provides inhibitors of proteins that activate the erythroblast transformation-specific proto-oncogene (2)(ETS2), and their use in the treatment or prevention of inflammatory and / or autoimmune diseases. Inhibitors are generally MEK inhibitors, HSP90 inhibitors, RAF inhibitors, SRC inhibitors, and / or ERK inhibitors. The present invention also encompasses diagnostic methods and methods for screening for agents that reduce macrophage activation.

Disclosed herein are methods of administering a Casitas B-lineage lymphoma proto-oncogene B inhibitor (CBL-Bi) for treating a cancer in a subject. Additionally disclosed herein are methods of administering a pre-treatment in combination with the CBL-Bi for treating a cancer in a subject.

The present application relates to the field of drug recommendation, in particular to a tumor-targeting drug recommendation method and system, the method comprising the following steps: providing gene expression information of a patient; obtaining a cancer cell ratio by using the gene expression information; determining a target gene by using the cancer cell ratio; providing a database comprising targeting drug information; generating a correlation model of targeting drugs and proto-oncogenes by using the database; optimizing the correlation model; obtaining targeting drug recommendation information by using the optimized correlation model in combination with the target gene; and integrating the targeting drug recommendation information to obtain a targeting drug recommendation table. The method takes the gene expression information of a patient as a basis, obtains a cancer cell ratio by calculation, and then determines a target gene, and further precisely matches the target gene with a current targeting drug, so that the most suitable tumor-targeting drug for the individual condition of a patient can be precisely determined and recommended in the case where a cancerous tissue biopsy sample cannot be obtained.